Articles mentioning Dendreon Corp (DNDN)

Results 1 - 10 of 453 : 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for DNDN

Investing | April 13, 2014

5 Innovations Wall Street and Investors Don't Understand How to Value

Innovation is the cornerstone to any successful business. However, Wall Street and investors don't have the slightest clue what the true valuation of these five innovations should be.

Investing | March 06, 2014

Biotech Earnings Checkup: CLDX, DNDN, OPX

Notable earnings reports in biotech this week.

Investing | March 04, 2014

Dendreon Corp.: The Biggest Loser in Biotech Today

Here's why shares of Dendreon backslid today, and lost so much of yesterday's market gain.

Investing | March 04, 2014

Today's Biggest Biotech Stories: Dendreon, AbbVie, and Omeros

Dendreon, AbbVie, and Omeros could all loom large in health-care headlines this morning. Here’s the news that you need to know.

Investing | March 03, 2014

Investors Are in Love With Dendreon Corporation

Despite a lackluster quarter where it trailed rivals Johnson & Johnson and Medication, investors sent sales of Dendreon up 15%.

Investing | March 03, 2014

Why Plug Power, Dendreon, and Pacific Ethanol Are Today's 3 Best Stocks

The S&P 500 sinks as the Ukranian crisis thickens while Plug Power, Dendreon, and Pacific Ethanol soar.

Investing | March 03, 2014

Why Dendreon Corporation Shares Soared

Dendreon shares soar for a change after reporting its fourth-quarter earnings results. Is this move sustainable or the perfect exit point for shareholders?

Investing | February 18, 2014

These 5 Cancer Immunotherapy Companies All Have 1 Thing in Common

Cancer immunotherapies are all the rage on Wall Street, but these five immunotherapy-focused companies all have one big thing in common.

Investing | February 17, 2014

3 Biotech Stocks to Avoid: Amarin, Dendreon, and Prosensa

Amarin, Dendreon, and Prosensa are three biotech stocks which should be avoided at all costs. Here’s why.

Investing | February 06, 2014

The Results of the "One Person's Trash Is Another Person's Treasure" Portfolio

Following a year of tracking 10 contrarian plays against the S&P 500, it's time to determine how we fared and what we learned from our experiment.

Results 1 - 10 of 453 : 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for DNDN